IS ANKTIVA RIGHT FOR YOU?
Go ahead and TRI.
Anktiva is an Immunotherapy that Activates Your Body’s Cancer Fighting Cells
Anktiva is the first U.S. FDA-approved immunotherapy that activates a type of cell called a natural killer (NK) cell, part of the body’s natural immune system, to attack and kill non-muscle invasive bladder cancer (NMIBC) cells.1 Anktiva is a treatment for use in combination with a standard treatment for NMIBC, bacillus Calmette-Guérin (BCG), for people with NMIBC for whom BCG alone was not effective or in whom NMIBC returned after initial successful treatment. These people have what is termed BCG-unresponsive NMIBC.
QUILT-3.032 Study
of study participants achieved a complete response, meaning their cancer was eliminated
(n=77; 95% CI: 51-73).1
Biopsy confirmed.
58% (n=28) ≥12 months; 40% (n=19) ≥24 months; range: 0.0–47.0+ months.1
+ Denotes an ongoing response.
Full Enrollment Follow-up
of study participants had a complete response
(n=100; 95% CI: 61.1-79.6).2
Biopsy confirmed.
Some patients remained NMIBC-free for over 4 years.2
+ Denotes an ongoing response.
QUILT-3.032 is a multicenter, single-arm study in adults with BCG-unresponsive high-risk NMIBC with CIS ± Ta/T1 papillary disease. Efficacy was evaluated in 77 adults (label), with updated follow-up in 100 patients. Patients received nogapendekin alfa inbakicept-pmln 400 mcg plus BCG weekly for 6 weeks, with re-induction permitted at month 3. The primary endpoint was complete response.1,2
References: 1. Anktiva (nogapendekin alfa inbakicept-pmln) prescribing information. ImmunityBio, 2024. 2. Chang, S. (2025, April 26-29). An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.
Who Should Consider Anktiva?
Anktiva is a treatment for adults who have all the following:
- High-risk non-muscle invasive bladder cancer (NMIBC)
- NMIBC that did not or is no longer responding to BCG therapy alone (BCG-unresponsive)
- NMIBC that has not grown beyond the inner lining of the bladder to the muscle underneath (called carcinoma in situ or CIS disease)
- NMIBC with or without small finger-like tumor growths that project away from the bladder wall into the bladder (papillary disease)
If You Have Been Diagnosed With BCG-Unresponsive NMIBC With CIS Disease and Are Interested in Anktiva, Here Is What You Need to Know:
What Anktiva is
- Anktiva is an immunotherapy that activates your body’s natural immune system
- Anktiva is used in combination with BCG and is administered directly into your bladder via a catheter intravesically
- Anktiva is the first treatment of its type approved to treat BCG-unresponsive NMIBC with CIS
What Anktiva is not
- Anktiva is not a chemotherapy
- Anktiva is not administered via IV. It only fights cancer in the bladder
- Anktiva is not an indirect mechanism, it directly stimulates the immune response
Getting Started With Anktiva
See how Anktiva works with BCG in the Tri-offense and what to expect before and after treatment
Patient Story
A Patient Like You
Read about a patient who participated in the clinical trials for Anktiva
Wayne’s Journey
Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who “just likes people.” When he was first told, “you might have a tumor in your bladder,” he became very concerned, especially when he learned his first treatment with BCG wasn’t working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.
When BCG Alone Isn’t Enough,
Bring On the Tri-Offense With Anktiva.
For more information, please call 1-877-ANKTIVA.
